Advances in adoptive immunotherapy to accelerate T-cellular immune reconstitution after HLA-incompatible hematopoietic stem cell transplantation

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 481-496

  Reimann, Christian ^a   Dal Cortivo, Liliane ^b   Hacein Bey Abina, Salima ^b,c   Fischer, Alain ^a,b,c   André Schmutz, Isabelle ^a,c   Cavazzana Calvo, Marina ^a,b,c  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

allodepletion; cytotoxic lymphocyte; ex vivo T cell precursor generation; immune reconstitution after HSCT; post transplant immunodeficiency; primary immunodeficiency

Indexed keywords

CD137 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; GONADORELIN AGONIST; GROWTH HORMONE; INTERLEUKIN 15; INTERLEUKIN 17; KERATINOCYTE GROWTH FACTOR; NOTCH RECEPTOR; RECOMBINANT HUMAN INTERLEUKIN 17; RECOMBINANT SOMATOMEDIN C; SEX HORMONE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; LYMPHOPOIESIS; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TREATMENT WITHDRAWAL;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

EID: 77955000343     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.36     Document Type: Article

References (109)

1. Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A: Gene therapy for severe combined immunodeficiency. Annu. Rev. Med. 56, 585-602 (2005).
2. Gaspar HB, Parsley KL, Howe S et al.: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gretroviral vector. Lancet 364, 2181-2187 (2004).
3. Neven B, Leroy S, Decaluwe H et al.: Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 113, 4114-4124 (2009).
4. Cavazzana-Calvo M, Carlier F, Le Deist F et al.: Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 109, 4575-4581 (2007).
5. Muller SM, Kohn T, Schulz AS, Debatin KM, Friedrich W: Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation. Blood 96, 4344-4349 (2000).
6. Chen BJ, Cui X, Liu C, Chao NJ: Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99, 3083-3088 (2002).
7. Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR: Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br. J. Haematol. 109, 644-651 (2000).
8. Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W: Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant. 37, 297-305 (2006).
9. Koh MB, Prentice HG, Lowdell MW: Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 23, 1071-1079 (1999).
10. Samarasinghe S, Mancao C, Pule M et al.: Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood 115, 396-407 (2010).
11. Solomon SR, Mielke S, Savani BN et al.: Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106, 1123-1129 (2005).
12. Hartwig UF, Robbers M, Wickenhauser C, Huber C: Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 99, 3041-3049 (2002).
13. Solomon SR, Tran T, Carter CS et al.: Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 4, 395-406 (2002).
14. Wehler TC, Nonn M, Brandt B et al.: Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 109, 365-373 (2007).
15. Godfrey WR, Krampf MR, Taylor PA, Blazar BR: Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 103, 1158-1165 (2004).
16. Cavazzana-Calvo M, Fromont C, Le Deist F et al.: Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 50, 1-7 (1990).
17. Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW: Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br. J. Haematol. 118, 108-116 (2002).
18. Amrolia PJ, Muccioli-Casadei G, Yvon E et al.: Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102, 2292-2299 (2003).
19. Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR: Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant. 25(Suppl. 2), S39-S42 (2000).
20. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S et al.: Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a Phase 1/2 study. Lancet 360, 130-137 (2002).
21. Amrolia PJ, Muccioli-Casadei G, Huls H et al.: Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108, 1797 - 1808 (2006).
22. +CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144-1150 (2003).
23. Taylor PA, Lees CJ, Blazar BR: The infusion of ex vivo activated and expanded CD4(+) CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
24. Mielke S, Rezvani K, Savani BN et al.: Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 110, 1689-1697 (2007).
25. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC: P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood 100, 375-382 (2002).
26. Roy DC, Busque L, Fish D et al.: Phase I clinical study of donor lymphocyte infusion depleted of alloreactive T cells after haplotype mismatched myeloablative stem cell transplantation to limit infections and malignant relapse without causing GvHD. Blood 108, 309 (2006).
27. Schwarer AP, Jiang YZ, Brookes PA et al.: Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 341, 203-205 (1993).
28. Mielke S, Nunes R, Rezvani K et al.: A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111, 4392-4402 (2008).
29. Perruccio K, Topini F, Tosti A et al.: Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol. Dis. 40, 76-83 (2008).
30. Perruccio K TF, Tosti A, Carotti A, Aloisi F, Aversa F: Adoptive immunotherapy after haploidentical stem cell transplantation with T-cells allodepleted by photodynamic purging. Bone Marrow Transplant. 41, S24-S25 (2008) (Abstract 172).
31. Andre-Schmutz I, Dal Cortivo L, Fischer A, Cavazzana-Calvo M: Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation. Cytotherapy 7, 102-108 (2005).
32. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-241 (1992).
33. Walter EA, Greenberg PD, Gilbert MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044 (1995).
34. Heslop HE, Ng CY, Li C et al.: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551-555 (1996).
35. Rooney CM, Smith CA, Ng CY et al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549-1555 (1998).
36. Beck O, Topp MS, Koehl U et al.: Generation of highly purified and functionally active human Th1 cells against Aspergillus fumigatus. Blood 107, 2562-2569 (2006).
37. Tramsen L, Koehl U, Tonn T et al.: Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant. 43, 13-19 (2009).
38. Li Pira G, Kapp M, Manca F, Einsele H: Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host. Curr. Opin. Immunol. 21, 549-556 (2009).
39. Hamel Y, Blake N, Gabrielsson S et al.: Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. Hum. Gene Ther.. 13, 855-866 (2002).
40. Leen AM, Myers GD, Sili U et al.: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12, 1160-1166 (2006).
41. Leen AM, Christin A, Myers GD et al.: Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114, 4283-4292 (2009).
42. Fry TJ, Mackall CL: Interleukin-7 and immunorestoration in HIV: beyond the thymus. J. Hematother. Stem Cell Res. 11, 803-807 (2002).
43. Fry TJ, Mackall CL: Interleukin-7: from bench to clinic. Blood 99, 3892-3904 (2002).
44. Watanabe M, Ueno Y, Yajima T et al.: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Invest. 95, 2945-2953 (1995).
45. Puel A, Ziegler SF, Buckley RH, Leonard WJ: Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 20, 394-397 (1998).
46. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE: IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 97, 1491-1497 (2001).
47. Parkman R, Weinberg KI: Immunological reconstitution following bone marrow transplantation. Immunol. Rev. 157, 73-78 (1997).
48. Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL: Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood 97, 1525-1533 (2001).
49. Alpdogan O, Muriglan SJ, Eng JM et al.: IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 112, 1095-1107 (2003).
50. Broers AE, Posthumus-van Sluijs SJ, Spits H et al.: Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants. Blood 102, 1534-1540 (2003).
51. Shultz LD, Lyons BL, Burzenski LM et al.: Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R g null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-6489 (2005).
52. Storek J, Gillespy T 3rd, Lu H et al.: Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood 101, 4209-4218 (2003).
53. Fry TJ, Moniuszko M, Creekmore S et al.: IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 101, 2294-2299 (2003).
54. Beq S, Nugeyre MT, Ho Tsong Fang R et al.: IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J. Immunol. 176, 914-922 (2006).
55. Sportes C, Hakim FT, Memon SA et al.: Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205, 1701-1714 (2008).
56. Sportes C, Babb RR, Krumlauf MC et al.: Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin. Cancer Res. 16, 727-735.
57. Dean RM, Fry T, Mackall C et al.: Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J. Clin. Oncol. 26, 5735-5741 (2008).
58. Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL: Interleukin 7 worsens graft-versus-host disease. Blood 100, 2642-2649 (2002).
59. Andre-Schmutz I, Bonhomme D, Yates F et al.: IL-7 effect on immunological reconstitution after HSCT depends on MHC incompatibility. Br. J. Haematol. 126, 844-851 (2004).
60. Chen Q, Khoury M, Chen J: Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc. Natl Acad. Sci. USA 106, 21783-21788 (2009).
61. Huntington ND, Legrand N, Alves NL et al.: IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 206, 25-34 (2009).
62. Williams KM, Hakim FT, Gress RE: T cell immune reconstitution following lymphodepletion. Semin. Immunol. 19, 318-330 (2007).
63. Alpdogan O, van den Brink MR: IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol. 26, 56-64 (2005).
64. Alpdogan O, Eng JM, Muriglan SJ et al.: Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105, 865-873 (2005).
65. + T cells. Proc. Natl Acad. Sci. USA 101, 1969-1974 (2004).
66. Danilenko DM, Montestruque S, Philo JS et al.: Recombinant rat fibroblast growth factor-16: structure and biological activity. Arch. Biochem. Biophys. 361, 34-46 (1999).
67. Farrell CL, Bready JV, Rex KL et al.: Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 58, 933-939 (1998).
68. Min D, Panoskaltsis-Mortari A, Kuro OM, Hollander GA, Blazar BR, Weinberg KI: Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood 109, 2529-2537 (2007).
69. Seggewiss R, Lore K, Guenaga FJ et al.: Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 110, 441-449 (2007). (Pubitemid 47026867)
70. Jenq RR, King CG, Volk C et al.: Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood 113, 1574-1580 (2009).
71. Spielberger R, Stiff P, Bensinger W et al.: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590-2598 (2004).
72. Stiff PJ, Emmanouilides C, Bensinger WI et al.: Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol. 24, 5186-5193 (2006).
73. Mackall CL, Gress RE: Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 157, 61-72 (1997).
74. Utsuyama M, Hirokawa K: Hypertrophy of the thymus and restoration of immune functions in mice and rats by gonadectomy. Mech. Ageing Dev. 47, 175-185 (1989).
75. Medina KL, Strasser A, Kincade PW: Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 95, 2059-2067 (2000).
76. Dudakov JA, Goldberg GL, Reiseger JJ, Vlahos K, Chidgey AP, Boyd RL: Sex steroid ablation enhances hematopoietic recovery following cytotoxic antineoplastic therapy in aged mice. J. Immunol. 183, 7084-7094 (2009).
77. Goldberg GL, Sutherland JS, Hammet MV et al.: Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation 80, 1604-1613 (2005).
78. Goldberg GL, Alpdogan O, Muriglan SJ et al.: Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation. J. Immunol. 178, 7473-7484 (2007).
79. Goldberg GL, King CG, Nejat RA et al.: Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J. Immunol. 182, 5846-5854 (2009).
80. Kelly RM, Highfill SL, Panoskaltsis-Mortari A et al.: Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood 111, 5734-5744 (2008).
81. Sutherland JS, Goldberg GL, Hammett MV et al.: Activation of thymic regeneration in mice and humans following androgen blockade. J. Immunol. 175, 2741-2753 (2005).
82. Sutherland JS, Spyroglou L, Muirhead JL et al.: Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade. Clin. Cancer Res. 14, 1138-1149 (2008).
83. Clark R: The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr. Rev. 18, 157-179 (1997).
84. Montecino-Rodriguez E, Clark R, Dorshkind K: Effects of insulin-like growth factor administration and bone marrow transplantation on thymopoiesis in aged mice. Endocrinology 139, 4120-4126 (1998).
85. Murphy WJ, Durum SK, Longo DL: Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice. Proc. Natl Acad. Sci. USA 89, 4481-4485 (1992).
86. Hanley MB, Napolitano LA, McCune JM: Growth hormone-induced stimulation of multilineage human hematopoiesis. Stem Cells 23, 1170-1179 (2005).
87. Huang S, Terstappen LW: Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38-hematopoietic stem cells. Blood 83, 1515-1526 (1994).
88. Chu YW, Schmitz S, Choudhury B et al.: Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 112, 2836-2846 (2008).
89. Alpdogan O, Muriglan SJ, Kappel BJ et al.: Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation 75, 1977-1983 (2003).
90. Robbins K, McCabe S, Scheiner T, Strasser J, Clark R, Jardieu P: Immunological effects of insulin-like growth factor-I - enhancement of immunoglobulin synthesis. Clin. Exp. Immunol. 95, 337-342 (1994).
91. Tian ZG, Woody MA, Sun R et al.: Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice. Stem Cells 16, 193-199 (1998).
92. Napolitano LA, Schmidt D, Gotway MB et al.: Growth hormone enhances thymic function in HIV-1-infected adults. J. Clin. Invest. 118, 1085-1098 (2008).
93. Ma NS, Shah AJ, Geffner ME, Kapoor N: IGF-I stimulates in vivo thymopoiesis after stem cell transplantation in a child with Omenn syndrome. J. Clin. Immunol. 30, 114-120.
94. Schmitt TM, Zuniga-Pflucker JC: Induction of T cell development from hematopoietic progenitor cells by Delta-like-1 in vitro. Immunity 17, 749-756 (2002).
95. Ohishi K, Varnum-Finney B, Bernstein ID: δ-1 enhances marrow and thymus repopulating ability of human CD34+ CD38-cord blood cells. J. Clin. Invest. 110, 1165-1174 (2002).
96. Radtke F, Wilson A, Mancini SJ, MacDonald HR: Notch regulation of lymphocyte development and function. Nat. Immunol. 5, 247-253 (2004).
97. Wolfer A, Wilson A, Nemir M, MacDonald HR, Radtke F: Inactivation of Notch1 impairs VDJβ rearrangement and allows pre-TCR-independent survival of early a b lineage thymocytes. Immunity 16, 869-879 (2002).
98. Ciofani M, Zuniga-Pflucker JC: Notch promotes survival of pre-T cells at the b-selection checkpoint by regulating cellular metabolism. Nat. Immunol. 6, 881-888 (2005).
99. Schmitt TM, Ciofani M, Petrie HT, Zuniga-Pflucker JC: Maintenance of T cell specification and differentiation requires recurrent notch receptor-ligand interactions. J. Exp. Med. 200, 469-479 (2004).
100. Pui JC, Allman D, Xu L et al.: Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11, 299-308 (1999).
101. Jaleco AC, Neves H, Hooijberg E et al.: Differential effects of Notch ligands d-1 and Jagged-1 in human lymphoid differentiation. J. Exp. Med. 194, 991-1002 (2001).
102. De Smedt M, Hoebeke I, Plum J: Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment. Blood Cells Mol. Dis. 33, 227-232 (2004).
103. La Motte-Mohs RN, Herer E, Zuniga-Pflucker JC: Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 105, 1431-1439 (2005).
104. Zuniga-Pflucker JC: T-cell development made simple. Nat. Rev. Immunol. 4, 67-72 (2004).
105. +8-a b T cell receptor positive T cells. Cell Immunol. 142, 385-397 (1992).
106. Zakrzewski JL, Kochman AA, Lu SX et al.: Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat. Med. 12, 1039-1047 (2006).
107. Zakrzewski JL, Suh D, Markley JC et al.: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat. Biotechnol. 26, 453-461.
108. Meek B, Cloosen S, Borsotti C et al.: In vitro-differentiated T/natural killer-cell progenitors derived from human CD34+ cells mature in the thymus. Blood 115, 261-264 (2008).
109. Lefort N, Benne C, Lelievre JD et al.: Short exposure to Notch ligand d-4 is sufficient to induce T-cell differentiation program and to increase the T cell potential of primary human CD34+ cells. Exp. Hematol. 34, 1720-1729 (2006).